

April 30, 2026

To,
The Listing Department,
BSE LIMITED,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai- 400 001

To,
The Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C-1,
G-Block, Bandra Kurla Complex,
Mumbai -400051

Scrip Code: 543349

NSE Symbol: ACUTAAS

Dear Sir / Madam,

**Sub: Disclosure under Regulation 30 and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'):
Outcome of the Board meeting**

In accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company at their meeting held on Thursday, April 30, 2026 at the Registered Office of the Company, inter alia, considered & approved the following resolutions/decisions:

1. The Audited Standalone & Consolidated Financial Results of the Company for the quarter and year ended 31st March, 2026 along with Auditor's Report on Standalone and consolidated Financial Results.
2. Recommendation of Final Dividend of Rs. 2.5/- (Rupees Two and fifty paise only, at the rate of 50%) per Equity Shares of Rs. 5/- each fully paid up (subject to deduction of tax, if any) on 8,18,71,122 numbers of Equity Shares of the Company, for the FY 2025-26 which shall be subject to the confirmation by Shareholders in the ensuing Annual General Meeting of Company.
3. Appointment of M/s Chirag Vallabhnbhai Vekariya & Co., a Cost and Management Accountants firm, having Firm Registration No. 001422, as the Cost Auditors of Company for the FY 2026-27.
4. Appointment of M/s K. C Mehta & Co. LLP., a Chartered Accountants, having Firm Registration No. 106237W, as the Internal Auditors of Company for the FY 2026-27.
5. In accordance with the Company's "Policy for Determination of Material Subsidiaries," and based on the latest audited consolidated financial statements, Indichem INC has met the prescribed thresholds and is now identified as a Material Subsidiary of the Company.

Brief details of the aforesaid changes as prescribed under SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/ CIR/P/0155 dated November 11, 2024, as Annexure A.



The Board Meeting commenced at 11.30 a.m. and concluded at 12.10 P.M.

We request you to please take the above information on your records.

For, ACUTAAS CHEMICALS LIMITED


Ekta Kumari

CS Ekta Kumari Srivastava

Company Secretary & Compliance Officer



Encl: Annexure 1



Independent Auditor's Report on Audit of Annual Consolidated Financial Results and Review of Quarterly Financial Results of the Parent Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**To The Board of Directors of
Acutaas Chemicals Limited**

Opinion

We have audited the accompanying statement of Consolidated Financial Results for the year ended March 31, 2026 and reviewed the Consolidated Financial Results for the quarter ended March 31, 2026 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Consolidated Financial Results for the Quarter and Year Ended March 31, 2026 of **Acutaas Chemicals Limited** (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as the "Group") and its share of the net profit after tax and other comprehensive income of its joint venture (the "Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

a) Opinion on Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Consolidated Financial Results for the year ended March 31, 2026:

- i. includes the financial results of the entities as given below:
 - a. Parent Company: Acutaas Chemicals Limited
 - b. Wholly owned Subsidiary Company: Acutaas Chemicals Electrolytes Private Limited
 - c. Wholly owned Subsidiary Company: Acutaas Advance Material Limited
 - d. Subsidiary: Baba Fine Chemicals (Partnership Firm)
 - e. Joint Venture: Ami Onco-Theranostics, LLC
 - f. Step down subsidiary: Enchem Ami Organics Private Limited
 - g. Step down subsidiary: Indichem Inc.
- ii. are presented in accordance with the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- iii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the group for the year then ended.

b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2026

With respect to the Consolidated Financial Results for the quarter ended March 31, 2026, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended March 31, 2026, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2026

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Group and its joint venture in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's and Board of Directors' Responsibilities for the Statement

This Statement which includes the Consolidated Financial Results is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2026 has been compiled from the related audited Consolidated Financial Statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2026 that give a true and fair view of the net profit and other comprehensive income and other financial information of the group including its joint venture in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations.

The respective Board of Directors of the companies included in the Group and its joint venture are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and its joint venture for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group and its joint venture are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors or the designated partners, as applicable either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and its joint venture are responsible for overseeing the financial reporting process of the Group and its joint venture.

Auditor's Responsibilities

a) Audit of the Consolidated Financial Results for the year ended March 31, 2026

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2026 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Annual Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the LODR Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's and its joint venture's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Annual Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its joint venture to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Annual Financial Results, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Annual Financial Results of the entities within the Group and its joint venture to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Annual Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Consolidated Annual Financial Results that individually or in aggregate, make it probable that the economic decisions of a reasonably knowledge user of Consolidated Annual Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated Annual Financial Results.

We communicate with those charged with governance of the Parent regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



b) Review of the Consolidated Financial Results for the quarter ended March 31, 2026

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2026 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Group's and its joint venture's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Other Matters

The Consolidated Annual Financial Results include the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year and the unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report on the Statement is not modified in respect of this matter.

Certain of these subsidiaries are located outside India whose financial statements/ financial and other information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been audited / reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Parent's management has converted the financial statements/financial and other information of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have audited / reviewed, as applicable, these conversion adjustments made by the Parent's management. Our opinion / conclusion, as applicable, in so far as it relates to the balances and affairs of such subsidiaries located outside India is based on the report of other auditors and the conversion adjustments prepared by the management of the Parent and audited by us.

Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

Place: Surat

Date: April 30, 2026



**For Maheshwari & Co.
Chartered Accountants
Firm's Registration No.105834W**

A handwritten signature in blue ink, appearing to read 'Vikas Asawa'.

**Vikas Asawa
Partner**

**Membership No. 172133
UDIN: 26172133EELULR1720**

**ACUTAAS CHEMICALS LIMITED**

(Formerly known as Ami Organics Limited)

CIN: L24100GJ2007PLC051093

Registered office: 440/4 5 6, Road No 82A, Sachin GIDC, Surat, Gujarat - 394 230, India

Tel: +91 72279 77744; +91 75730 15366

Website: www.acutaas.com Email: cs@acutaas.com

Consolidated Financial Results for the Quarter & Year Ended March 31, 2026

(₹ in lakhs, unless otherwise stated)

Particulars	Quarter Ended			Year Ended	Year Ended
	March 31, 2026	December 31, 2025	March 31, 2025	March 31, 2026	March 31, 2025
	Unaudited	Unaudited	Unaudited	Audited	Audited
Income					
Revenue from operations	43,275.05	39,318.33	30,848.34	133,936.68	100,687.55
Other income	1,111.10	469.92	577.91	4,158.52	1,692.94
Total income	44,386.15	39,788.25	31,426.25	138,095.20	102,380.49
Expenses					
Cost of materials consumed	18,368.60	17,597.45	16,455.18	59,495.95	56,981.13
Changes in inventories of finished goods, stock-in-trade and work-in-progress	(1,924.52)	(680.10)	(206.86)	(2,900.34)	(1,762.96)
Employee benefits expenses	3,328.86	2,985.66	2,330.12	11,757.19	8,365.59
Finance costs	118.97	86.12	60.32	326.81	621.84
Depreciation and amortization expenses	963.03	982.49	729.82	3,598.76	2,662.14
Other expenses	5,151.04	4,349.78	3,774.23	17,544.26	13,896.45
Total expenses	26,005.98	25,321.40	23,142.81	89,822.63	80,764.19
Profit before tax	18,380.17	14,466.85	8,283.44	48,272.57	21,616.30
Tax expense					
Current tax	4,883.13	3,637.46	1,550.58	11,719.75	4,918.95
Deferred tax	68.67	207.47	461.25	915.89	655.58
Total tax expense	4,951.80	3,844.93	2,011.83	12,635.64	5,574.53
Profit for the period	13,428.37	10,621.92	6,271.61	35,636.93	16,041.77
Other comprehensive income					
Items that will not be reclassified to profit or loss					
Remeasurement of defined employee benefit plans	28.78	(21.34)	40.34	(35.02)	(17.48)
Tax impact on items that will not be reclassified to profit or loss	(8.01)	5.49	(10.90)	8.46	3.67
Items that will be reclassified to profit or loss					
Exchange differences on translation of financial statements of foreign entity	(336.67)	40.79	-	(295.88)	-
Other comprehensive income	(315.89)	24.94	29.44	(322.44)	(13.81)
Total comprehensive income for the period	13,112.48	10,646.86	6,301.05	35,314.49	16,027.96
Profit attributable to					
Owners of the company	13,176.08	10,796.05	6,248.28	35,625.53	15,871.36
Non - controlling interest	252.29	(174.13)	23.33	11.40	170.41
Other comprehensive income attributable to					
Owners of the company	(316.22)	24.73	31.99	(323.49)	(12.51)
Non - controlling interest	0.32	0.21	(2.55)	1.05	(1.30)
Paid up equity share capital (face value of ₹ 5 each)	4,093.56	4,093.56	4,093.45	4,093.56	4,093.45
Other equity				161,262.54	126,869.42
Earnings per equity share of ₹ 5 each (not annualised, excluding year end)					
Basic (₹)	16.09	13.19	7.80	43.51	19.81
Diluted (₹)	16.04	13.10	7.80	43.37	19.81

For Acutaas Chemicals Limited

Place: Surat
Date: April 30, 2026Nareshkumar Ramjibhai Patel
Chairman & Managing Director
DIN: 00906232

ACUTAAS CHEMICALS LIMITED

(Formerly known as Ami Organics Limited)

CIN: L24100GJ2007PLC051093

Registered office: 440/4 5 6, Road No 82A, Sachin GIDC, Surat, Gujarat - 394 230, India

Tel: +91 72279 77744; +91 75730 15366

Website: www.acutaas.com Email: cs@acutaas.com

Consolidated Balance Sheet as at March 31, 2026

Rs. in Lakhs

Particulars	As at	
	March 31, 2026	March 31, 2025
	Audited	Audited
ASSETS		
Non-current assets		
Property, plant and equipment	58,279.91	46,292.28
Capital work-in-progress	33,231.79	13,028.40
Right-of-use assets	5,052.44	4,239.03
Goodwill	10,434.10	5,680.09
Intangible assets	719.18	827.51
Financial Assets		
i) Investments	19.54	19.53
ii) Other financial assets	822.20	493.24
Income tax assets (net)	-	15.31
Other non-current assets	1,710.30	5,167.12
Total non-current assets	110,269.46	75,762.51
Current assets		
Inventories	23,132.37	17,994.02
Financial assets		
i) Trade receivables	36,256.32	29,049.47
ii) Cash and cash equivalents	21,555.11	18,522.43
iii) Bank balances other than cash and cash equivalents	928.32	6,370.40
iv) Loans	259.96	215.98
Other current assets	5,994.89	7,011.30
Total current assets	88,126.97	79,163.60
Total assets	198,396.43	154,926.11
EQUITY AND LIABILITIES		
Equity		
Equity share capital	4,093.56	4,093.45
Other equity	161,262.54	126,869.42
Equity attributable to owners of the Company	165,356.10	130,962.87
Non controlling interests	5,718.92	1,045.17
Total equity	171,075.02	132,008.04
Non-current liabilities		
Financial liabilities		
i) Lease liabilities	910.51	475.44
Provisions	458.83	254.64
Deferred tax liabilities (net)	2,870.67	1,963.25
Total non-current liabilities	4,240.01	2,693.33
Current liabilities		
Financial liabilities		
i) Borrowings	2,649.08	818.43
ii) Trade payables		
a) Total outstanding dues of micro enterprises and small enterprises	2,718.49	5,432.27
b) Total outstanding dues of other than micro enterprises and small enterprises	12,672.18	10,172.30
Other current liabilities	1,243.95	1,347.74
Provisions	3,250.02	2,454.00
Current tax liabilities (net)	547.68	-
Total current liabilities	23,081.40	20,224.74
Total liabilities	27,321.41	22,918.07
Total equity and liabilities	198,396.43	154,926.11

For Acutaas Chemicals Limited



Nareshkumar Ramji Patel
Chairman & Managing Director

DIN: 00906232

Place: Surat

Date: April 30, 2026

ACUTAAS CHEMICALS LIMITED

(Formerly known as Ami Organics Limited)

CIN: L24100GJ2007PLC051093

Registered office: 440/4 5 6, Road No 82A, Sachin GIDC, Surat, Gujarat - 394 230, India

Tel: +91 72279 77744; +91 75730 15366

Website: www.acutaas.com Email: cs@acutaas.com

Consolidated Statement of Cash Flow for the year ended March 31, 2026

Rs. in Lakhs

Particulars		For The Year Ended	
		March 31, 2026	March 31, 2025
		Audited	Audited
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit before Tax		48,272.57	21,616.30
Adjustments for:			
Depreciation and amortisation		3,598.76	2,662.14
(Gain)/Loss on disposal of property, plant and equipment		(1.45)	(1.43)
(Gain)/Loss on investments measured at fair value through profit and loss		(295.88)	-
Bad debts, provision for trade receivables and advances		(55.30)	208.71
Interest paid		306.21	621.84
Interest Income		(854.49)	(1,079.58)
ESOS compensation expenses		317.60	92.59
Dividend income		-	(0.04)
Unrealised (gain) / loss		(1,602.47)	(611.89)
Operating profit before working capital changes		49,685.55	23,508.64
Movement in working capital			
(increase) / decrease in trade receivables		(5,549.08)	(8,011.08)
(increase) / decrease in loans & advances		(43.98)	(60.92)
(increase) / decrease in other financial assets		(328.96)	(235.52)
(increase) / decrease in inventories		(5,138.35)	(2,320.61)
(increase) / decrease in other current assets		1,016.41	524.19
Increase / (decrease) in trade payables		(213.90)	2,143.69
Increase / (decrease) in other liabilities		104.73	(280.31)
Increase / (decrease) in provisions		841.70	1,239.96
Cash generated from operations		40,374.12	16,508.04
Income tax paid (net)		(11,156.76)	(4,673.77)
Net cash (used)/generated by operating activities	(A)	29,217.36	11,834.27
CASH FLOWS FROM INVESTING ACTIVITIES			
Investment in fixed deposit not considered as cash or cash equivalents		5,442.08	(4,009.65)
Purchase of property, plant and equipment			
(including CWIP, intangible assets and including capital advances)		(32,797.88)	(19,464.29)
Right of Use Asset			
Purchase of Investment		(0.01)	-
Incidental Charges towards purchase of Investment		(92.98)	-
Dividend received		-	0.04
Interest received		854.49	1,079.58
Net cash (used in) / generated by investing activities	(B)	(26,594.30)	(22,394.32)
CASH FLOWS FROM FINANCING ACTIVITIES			
Net Proceeds / (Repayment) from long term borrowings		-	(11,364.12)
Net Proceeds / (Repayment) from short term borrowings		1,830.65	(9,482.11)
Interest paid		(127.80)	(619.79)
Repayment of lease liabilities		(66.30)	(33.64)
Dividend paid (including tax on dividend)		(1,228.03)	(1,227.83)
Issue of equity shares		1.10	49,938.89
Share issue expense		-	(1,099.36)
Net cash (used)/generated by financing activities	(C)	409.62	26,112.04
Net increase / (decrease) in cash and cash equivalents	(A+B+C)	3,032.68	15,551.99
Cash and cash equivalents at the beginning of the year		18,522.43	3,970.44
Cash and cash equivalents at the end of the year		21,555.11	18,522.43

For Acutaas Chemicals Limited



Narech Kumar Ramjibhai Patol
Chairman & Managing Director
DIN: 00906232

Place: Surat
Date: April 30, 2026

Notes to the Consolidated Financial Results for the quarter | year ended March 31, 2026

1. The above consolidated financial results for the quarter | year ended March 31, 2026, which includes the financial information of Acutaas Chemicals Limited (Formerly known as Ami Organics Limited) ("the Company"), its subsidiary entities namely, Acutaas Chemicals Electrolytes Private Limited (formerly known as Ami Organics Electrolytes Private Limited), Acutaas Advance Material Limited (formerly known as Baba Advance Materials Limited) and Baba Fine Chemicals (collectively "the group"), its step down subsidiary entities namely, Enchem Ami Organics Private Limited and Indichem Inc. and its joint venture namely, Ami Onco-Theranostics LLC, were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on April 30, 2026. The Statutory Auditors of the Company have carried out an audit of the consolidated audited financial results for the quarter | year ended on March 31, 2026. Their audit report does not have any modification.
2. The above consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended.
3. As the Company operates in Single Segment only i.e. Custom synthesis and manufacturing of Speciality Chemicals having application in Pharmaceuticals API and others. it did not give rise to different operating segments in accordance with Ind AS 108 - Operating Segments.
4. The Board of Directors of the Company at their meeting held on February 21, 2025 and the Shareholders through postal ballot passed on March 26, 2025 have approved the sub-division/ split of each equity share of face value of Rs.10/- (Rupees Ten only) each, fully paid-up, into (two) equity shares having face value of Rs. 5/- (Rupees five only) each, fully paid-up. The record date for the said sub-division/ split was April 25, 2025. The basic and diluted EPS disclosed above have been adjusted to give effect to such sub-division/split in accordance with requirements under Ind AS 33, Earnings per share.
5. In accordance with Regulation 30 read with Schedule III of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, Acutaas Advance Material Limited ("AAML") (formerly known as Baba Advance Materials Limited), wholly owned subsidiary company of Acutaas Chemicals Limited has entered into a joint venture agreement with J & Materials Co. Ltd., a South Korean Company, whereby AAML shall hold 75% of the share capital of the joint venture company Indichem Inc. ("JV Company") a South Korean Company and the remaining 25% of the share capital of the JV Company will be held by J & Materials Co. Ltd., effectively from June 27, 2025. AAML has made an investment of approximately Rs. 190.52 crores in Indichem Inc. ("JV Company") by way of subscription to the equity shares for acquisition of 75% of equity share capital of Indichem Inc. by the quarter | year ended March 31, 2026.
6. On November 21, 2025, the Government of India notified four Labour Codes. effective immediately, replacing the then existing 29 labour laws. In accordance with Ind AS 19 - Employee benefits, changes to employee benefit plans arising from legislative amendments are treated as plan amendments requiring immediate recognition of changes in the past service cost in the standalone financial results. This approach is consistent with the guidance issued by the Institute of Chartered Accountants of India. Accordingly, the Company has assessed the impact of these changes and no material impact has been noticed under employee benefit expenses in the standalone audited financial results for the quarter | year ended on March 31, 2026.
7. The Nomination and Remuneration Committee of the Board of Directors of the Company at its meeting held on December 22, 2025 has granted 3,25,009 Options to vest over four consecutive years in tranches at an exercise price of Rs. 305/- per option, pursuant to the Ami Organics Employees' Stock Option Scheme 2023 ("ESOS 2023") to the eligible employees of the Company.
8. The Board of Directors has recommended a dividend of Rs. 2.50/- per share (50%) subject to the approval of the shareholders.
9. The previous periods/year's numbers have been regrouped/ rearranged wherever necessary to confirm the current period/year presentation.
10. The figures for the quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and the limited reviewed year to date figures up to the third quarter of the relevant financial year.



11. The results of the company are available at Company's website www.acutaas.com and also on the website of BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com where the shares of the Company are listed.



Date: April 30, 2026
Place: Surat



For and behalf of Board of Directors of
Acutaas Chemicals Limited
(Formerly known as Ami Organics Limited)

A handwritten signature in blue ink, appearing to read "Nareshkumar Ramjibhai Patel".

Nareshkumar Ramjibhai Patel
Chairman & Managing Director
DIN: 00906232

Independent Auditor's Report on Audit of Annual Standalone Financial Results and Review of Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**To The Board of Directors of
Acutaas Chemicals Limited**

Opinion

We have audited the accompanying statement of Standalone Financial Results for the year ended March 31, 2026 and reviewed the Standalone Financial Results for the quarter ended March 31, 2026 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Standalone Financial Results for the Quarter and Year Ended March 31, 2026 of **Acutaas Chemicals Limited** (the "Company"), (the "Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

a) Opinion on Annual Standalone Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2026:

- i. are presented in accordance with the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year then ended.

b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2026

With respect to the Standalone Financial Results for the quarter ended March 31, 2026, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2026, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2026

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.



Management's and Board of Directors' Responsibilities for the Statement

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2026 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2026 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors is responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities

a) Audit of the Standalone Financial Results for the year ended March 31, 2026

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2026 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the LODR Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the Company to express an opinion on the Annual Standalone Financial Results.

Materiality is the magnitude of misstatements in the standalone annual financial results that individually or in aggregate, make it probable that the economic decisions of a reasonably knowledge user of standalone annual financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone annual financial results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

b) Review of the Standalone Financial Results for the quarter ended March 31, 2026

We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2026 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Other Matters

The standalone annual financial results include the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year and the unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report on the Statement is not modified in respect of this matter.

Place: Surat

Date: April 30, 2026



For Maheshwari & Co.
Chartered Accountants
Firm's Registration No.105834W

A handwritten signature in blue ink, appearing to read "Vikas Asawa".

Vikas Asawa
Partner

Membership No. 172133
UDIN: 26172133JNCKQT8346

**ACUTAAS CHEMICALS LIMITED**

(Formerly known as Ami Organics Limited)

CIN: L24100GJ2007PLC051093

Registered office: 440/4 5 6, Road No 82A, Sachin GIDC, Surat, Gujarat - 394 230, India

Tel: +91 72279 77744; +91 75730 15366

Website: www.acutaas.com Email: cs@acutaas.com

Standalone Financial Results for the Quarter & Year Ended March 31, 2026

(₹ in lakhs, unless otherwise stated)

Particulars	Quarter Ended			Year Ended	Year Ended
	March 31, 2026	December 31, 2025	March 31, 2025	March 31, 2026	March 31, 2025
	Unaudited	Unaudited	Unaudited	Audited	Audited
Income					
Revenue from operations	42,177.23	39,085.56	30,416.14	132,379.22	98,983.46
Other income	1,454.59	634.28	569.42	4,587.83	1,833.56
Total Income	43,631.82	39,719.84	30,985.56	136,967.05	100,817.02
Expenses					
Cost of materials consumed	18,327.47	17,602.18	16,321.40	59,249.92	56,684.02
Changes in inventories of finished goods, stock-in-trade and work-in-progress	(2,063.77)	(864.31)	(197.87)	(3,068.80)	(1,864.56)
Employee benefits expenses	3,133.43	2,697.42	2,261.00	11,134.98	8,094.72
Finance costs	107.19	81.37	38.33	307.72	585.74
Depreciation and amortization expenses	883.00	901.77	655.65	3,303.22	2,404.52
Other expenses	4,658.41	4,230.95	3,625.86	16,762.62	13,555.05
Total expenses	25,045.73	24,649.38	22,704.37	87,689.66	79,459.49
Profit/(loss) before tax	18,586.09	15,070.46	8,281.19	49,277.39	21,357.53
Tax expense					
Current tax	4,705.39	3,635.64	1,522.94	11,549.05	4,697.08
Deferred tax	173.58	278.27	473.57	1,110.89	705.83
Total tax expense	4,878.97	3,913.91	1,996.51	12,659.94	5,402.91
Profit for the period	13,707.12	11,156.55	6,284.68	36,617.45	15,954.62
Other comprehensive income (OCI)					
Items that will not be reclassified to profit or loss					
Remeasurement of defined employee benefit plans	26.83	(21.81)	46.92	(38.60)	(14.59)
Tax impact on items that will not be reclassified to profit or loss	(6.76)	5.49	(11.81)	9.71	3.67
Total other comprehensive income (net of tax)	20.07	(16.32)	35.11	(28.89)	(10.92)
Total comprehensive income for the period	13,727.19	11,140.23	6,319.79	36,588.56	15,943.70
Details of equity share capital	4,093.56	4,093.56	4,093.45	4,093.56	4,093.45
Equity shares of face value Rs. 5/- each					
Other equity				162,745.21	127,066.07
Earnings per equity share of ₹ 5/- each (not annualised, excluding year end)					
Basic (₹)	16.74	13.63	7.84	44.73	19.91
Diluted (₹)	16.64	13.58	7.84	44.58	19.91

For Acutaas Chemicals Limited

Date: April 30, 2026
Place: SuratNareshkumar Ramjibhai Patel
Chairman & Managing Director
DIN: 00906232

ACUTAAS CHEMICALS LIMITED

(Formerly known as Ami Organics Limited)

CIN: L24100GJ2007PLC051093

Registered office: 440/4 5 6, Road No 82A, Sachin GIDC, Surat, Gujarat - 394 230, India

Tel: +91 72279 77744; +91 75730 15366

Website: www.acutaas.com Email: cs@acutaas.com

Standalone Balance Sheet as at March 31, 2026

Rs. in Lakhs

Particulars	As at	
	March 31, 2026	March 31, 2025
	Audited	Audited
ASSETS		
Non-current assets		
Property, plant and equipment	54,915.53	45,380.90
Capital work-in-progress	22,843.17	13,028.41
Right-of-use assets	4,905.86	4,210.47
Intangible assets	262.74	331.50
Financial Assets		
i) Investments	11,765.84	6,773.10
ii) Loans	15,421.84	330.36
iii) Other financial assets	973.78	1,235.59
Other non-current assets	1,561.16	5,167.12
Total non-current Assets	112,649.92	76,457.45
Current assets		
Inventories	22,667.20	17,400.12
Financial assets		
i) Trade receivables	36,017.91	28,921.19
ii) Cash and cash equivalents	16,004.17	18,460.70
iii) Bank balances other than cash and cash equivalents	495.97	5,611.76
iv) Loans	253.82	214.58
v) Other financial assets	386.75	206.69
Other current assets	5,069.68	6,522.98
Total current assets	80,895.50	77,338.02
Total assets	193,545.42	153,795.47
EQUITY AND LIABILITIES		
Equity		
Equity share capital	4,093.56	4,093.45
Other equity	162,745.20	127,066.07
Total equity	166,838.76	131,159.52
Non-current liabilities		
Financial liabilities		
i) Lease liabilities	798.24	475.44
Provisions	414.65	220.65
Deferred tax liabilities (net)	3,137.09	2,035.91
Total non-current liabilities	4,349.98	2,732.00
Current liabilities		
Financial liabilities		
i) Borrowings	2,405.04	634.90
ii) Trade Payables		
a) Total outstanding dues of micro enterprises and small enterprises	2,718.00	5,432.27
b) Total outstanding dues of other than micro enterprises and small enterprises	12,365.77	10,121.37
Provisions	3,232.93	2,408.11
Other current liabilities	1,116.82	1,305.51
Current tax liabilities (net)	518.12	1.79
Total current liabilities	22,356.68	19,903.95
Total liabilities	26,706.66	22,635.95
Total equity and liabilities	193,545.42	153,795.47

For Acutaas Chemicals Limited



Nareshkumar R Patel

Chairman & Managing Director

DIN: 00906232

Date: April 30, 2026

Place: Surat

ACUTAAS CHEMICALS LIMITED

(Formerly known as Ami Organics Limited)

CIN: L24100GJ2007PLC051093

Registered office: 440/4 5 6, Road No 82A, Sachin GIDC, Surat, Gujarat - 394 230, India

Tel: +91 72279 77744; +91 75730 15366

Website: www.acutaas.com Email: cs@acutaas.com

Standalone Statement of Cash Flow for the year ended March 31, 2026

Rs. in Lakhs

Particulars		For The Year Ended	
		March 31, 2026	March 31, 2025
		Audited	Audited
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit before tax		49,277.39	21,357.53
Adjustments for:			
Depreciation and amortisation		3,303.22	2,404.52
(Gain)/loss on disposal of property, plant and equipment		-	(1.43)
Bad debts, provision for trade receivables and advances		(55.30)	208.71
Finance cost		287.29	585.74
Interest Income		(1,154.72)	(1,029.50)
Share of profit from partnership firm		(180.06)	(206.69)
Employee compensation expenses		317.60	92.59
Dividend income		-	(0.04)
Unrealised (gain) / loss		(1,602.47)	(593.50)
Operating profit before working capital changes		50,192.95	22,817.93
Movement in working capital			
(increase) / decrease in trade receivables		(5,438.95)	(7,258.54)
(increase) / decrease in loans & advances		(39.24)	(142.95)
(increase) / decrease in other financial assets		261.81	(960.17)
(increase) / decrease in inventories		(5,267.08)	(2,281.14)
(increase) / decrease in other current assets		1,453.30	515.19
Increase / (decrease) in trade payables		(469.87)	2,224.89
Increase / (decrease) in other liabilities		19.83	(215.29)
Increase / (decrease) in provisions		856.76	1,264.48
Cash generated/(used) in operations		41,569.51	15,964.40
Income tax paid (net)		(11,032.72)	(4,371.61)
Net cash (used)/generated by operating activities	(A)	30,536.79	11,592.79
CASH FLOWS FROM INVESTING ACTIVITIES			
Investment in fixed deposit not considered as cash or cash equivalents		5,115.79	(5,366.15)
Purchase of property, plant and equipment (including CWIP, intangible assets and capital advances)		(19,547.61)	(19,100.60)
Purchase of investment		(4,992.74)	0.00
Loan and Advances (net)		(15,091.48)	-
Dividend received		-	0.04
Interest received		1,154.72	1,029.50
Net cash (used in) /generated by investing activities	(B)	(33,361.32)	(23,437.21)
CASH FLOWS FROM FINANCING ACTIVITIES			
Net proceeds / (repayment) from short term borrowings		1,770.14	(8,273.95)
Net proceeds / (repayment) from long term borrowings		-	(11,364.12)
Finance cost		(108.91)	(583.69)
Repayment of lease liabilities		(66.30)	(33.64)
Dividend paid		(1,228.03)	(1,227.83)
Issue of equity shares		1.10	49,938.88
Share issue expense		-	(1,099.36)
Net cash (used)/generated by financing activities	(C)	368.00	27,356.29
Net increase / (decrease) in cash and cash equivalents	(A+B+C)	(2,456.53)	15,511.87
Cash and cash equivalents at the beginning of the year		18,460.70	2,948.83
Cash and cash equivalents at the end of the year		16,004.17	18,460.70

For Acutaas Chemicals Limited

Date: April 30, 2026
Place: Surat



Naresh Kumar R Patel
Naresh Kumar R Patel
Chairman & Managing Director
DIN: 00906232

Notes to Standalone Financial Results for the quarter | year ended March 31, 2026

1. The above standalone financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on April 30, 2026.
2. The above standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended.
3. As the Company operates in Single Segment only i.e. Custom synthesis and manufacturing of Speciality Chemicals having application in Pharmaceuticals API and others, it did not give rise to different operating segments in accordance with Ind AS 108 - Operating Segments.
4. The Board of Directors of the Company at their meeting held on February 21, 2025 and the Shareholders through postal ballot passed on March 26, 2025 have approved the sub-division/ split of each equity share of face value of Rs.10/- (Rupees Ten only) each, fully paid-up, into (two) equity shares having face value of Rs. 5/- (Rupees five only) each, fully paid-up. The record date for the said sub-division/ split was April 25, 2025. The basic and diluted EPS disclosed above have been adjusted to give effect to such sub-division/split in accordance with requirements under Ind AS 33, Earnings per share.
5. On November 21, 2025, the Government of India notified four Labour Codes. effective immediately, replacing the then existing 29 labour laws. In accordance with Ind AS 19 - Employee benefits, changes to employee benefit plans arising from legislative amendments are treated as plan amendments requiring immediate recognition of changes in the past service cost in the standalone financial results. This approach is consistent with the guidance issued by the Institute of Chartered Accountants of India. Accordingly, the Company has assessed the impact of these changes and no material impact has been noticed under employee benefit expenses in the standalone audited financial results for the quarter I year ended on March 31, 2026.
6. The Nomination and Remuneration Committee of the Board of Directors of the Company at its meeting held on December 22, 2025 has granted 3,25,009 Options to vest over four consecutive years in tranches, at an exercise price of Rs. 305/- per option, pursuant to the Ami Organics Employees' Stock Option Scheme 2023 ("ESOS 2023") to the eligible employees of the Company.
7. The Board of Directors has recommended a dividend of Rs. 2.50/- per share (50%) subject to the approval of the shareholders.
8. The previous periods/year's numbers have been regrouped/ rearranged wherever necessary to confirm the current period/year presentation.
9. The figures for the quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and the limited reviewed year to date figures up to the third quarter of the relevant financial year.
10. The results of the company are available at Company's website www.acutaas.com and also on the website of BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com where the shares of the Company are listed.



For and behalf of Board of Directors of
Acutaas Chemicals Limited
(Formerly known as Ami Organics Limited)

Nareshkumar Ramjibhai Patel
Chairman & Managing Director
DIN: 00906232

Date: April 30, 2026
Place: Surat

Date: April 30, 2026

To,
The Board of Directors,
Acutaas Chemicals Limited,
Plot No. 440/4, 5 & 6, Road No. 82/A,
GIDC Sachin,
Surat 394230

Subject: Declaration pursuant to Regulation to 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

In Compliance with the Regulation to 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, I, Bhavin N. Shah, Chief Financial Officer of Acutaas Chemicals Limited ("the Company") hereby declare that M/s. Maheshwari & Co. Chartered Accountants (Firm Registration No. 105834W) Statutory Auditors of the Company, have issued Audit Report(s) on the Audited Standalone Financial Statements & Results of the Company, for the financial year ended on 31st March, 2026, with unmodified opinion.

Please take the above on record and may please be submitted to respective exchanges.

Thanking You,

For Acutaas Chemicals Limited



Bhavin N. Shah
Chief Financial Officer

Place: Surat



Date: April 30, 2026

To,
The Board of Directors,
Acutaas Chemicals Limited,
Plot No. 440/4, 5 & 6, Road No. 82/A,
GIDC Sachin,
Surat 394230

Subject: Declaration pursuant to Regulation to 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.


Dear Sir/Madam,

In Compliance with the Regulation to 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, I, Bhavin N. Shah, Chief Financial Officer of Acutaas Chemicals Limited ("the Company") hereby declare that M/s. Maheshwari & Co. Chartered Accountants (Firm Registration No. 105834W) Statutory Auditors of the Company, have issued Audit Report(s) on the Audited Consolidated Financial Statements & Results of the Company, for the financial year ended on 31st March, 2026, with unmodified opinion.

Please take the above on record and may please be submitted to respective exchanges.

Thanking You,

For Acutaas Chemicals Limited



Bhavin N. Shah
Chief Financial Officer



Place: Surat

ANNEXURE 1

Particulars	Cost Auditor	Internal Auditor
Name of Auditor	M/s Chirag Vekariya & Co. FRN: 001422	M/s K. C Mehta & Co. LLP FRN: 106237W
Reason for change viz. appointment, resignation, removal, death or otherwise.	Re-appointment	Re-appointment
Effective Date	April 30, 2026	April 30, 2026
Term of Appointment	To conduct Cost Audit for F.Y 2026-27	To conduct Internal Audit for F.Y 2026-27
Profile	Chirag Vallabhbhai Vekariya is a Surat based practising Cost & Management Consultant having experience for over 8 years. He has experience in installation of Cost management systems, budgetary Control systems, inventory control systems, conduct of cost audit, operation and management audit in varied industries like pharmaceuticals, Engineering, chemicals industries.	K C Mehta & Co. LLP is a Vadodara headquartered firm of Chartered Accountants, been in existence for 66 years. Over the years it has expanded into a dynamic professional organisation that offers a spectrum of financial services to diverse clientele. The firm has rich experience in Internal audit, statutory audit, tax audits, tax consultancy, legal advisory, data analytics, costing system etc. and performing internal audit under all ERP environments.

